Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Kit for activating prostatic cancer specific immunity response

A technology for prostate cancer and immune response, applied to blood/immune system cells, medical preparations containing active ingredients, animal cells, etc.

Inactive Publication Date: 2016-01-06
SHANGHAI LONGYAO BIOTECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, DC1 cells highly expressing IL12 loaded with tumor-specific antigen peptides can provide a strategy for enhancing the efficacy of antigen peptide-based tumor therapy, but there is no corresponding, mature and suitable for the activation of prostate cancer in the prior art. Kits for Patient-Specific Immune Responses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for activating prostatic cancer specific immunity response
  • Kit for activating prostatic cancer specific immunity response
  • Kit for activating prostatic cancer specific immunity response

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1 (cell culture supernatant is T cell culture supernatant)

[0034] When the kit of the present invention is used to activate the specific immune response of the prostate cancer patient, the preparation of type 1 polarized dendritic cells (type1 polarized dendritic cells, DC1) derived from adult peripheral blood is firstly performed. Peripheral blood mononuclear cells were isolated according to the method described by Jonuleit et al. (GeneTher. 200310(3)). First, peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and plasma was collected for subsequent culture. By density 3.0×10 6 / ml, the cells were inoculated into T75 culture flasks, and 10% plasma was added to the GGT551 medium, placed at 37.0°C, saturated humidity, 5% CO 2 cultivated in the environment. After culturing for 3 hours, the suspended lymphocytes were washed away, and DMEM / F12 medium containing GM-CSF and IL-4 1000 IU / ml and 10% plasma was ad...

Embodiment 2

[0039] Embodiment two (cell culture supernatant is NK cell and K562 cell co-culture supernatant)

[0040] Peripheral blood mononuclear cells were isolated according to the method described by Jonuleit et al. (GeneTher. 200310(3)). First, peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and plasma was collected for subsequent culture. IL-2 (2000U / ml) and IL15 (2ng / ml) were added. Doubling the medium every two to three days, and supplementing the factors in equal amounts. Collected on the twelfth day. After the induction is completed, NK cells are treated by 1-3×10 6 / ml was inoculated into medium RPMI1640, IFNa (1000UI / ml) was added and 0.5-1.5×10 5 Inoculate K562 cells (can be replaced with K562-NK cells) at a density of / ml for mixed culture, collect the medium supernatant during 24-48 hours of activation, filter and freeze at -80 degrees or directly use it for the preparation of DC1 cells. Peripheral blood mononuclear ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a kit for activating prostatic cancer specific immunity response. The kit comprises an RPMI-1640 culture medium, a cell culture supernatant, a GM-CSF, an IL-4, an INF gamma and a prostatic cancer specific antigenic peptide combination. The cell culture supernatant is an NK cell and K562 cell co-culture supernatant or a T cell culture supernatant. The prostatic cancer specific antigenic peptide combination includes SSX-2-A2 antigenic peptides, PIWIL2-A2 antigenic peptides, PAP-A2 antigenic peptides, PSA-A2 antigenic peptides, PSA-A3 antigenic peptides, hTERT-A2 antigenic peptides, hTERT-A3 antigenic peptides, Survivin-A2 antigenic peptides, Survivin-A3 antigenic peptides, PSCA-A2 antigenic peptides, COX-2-A2 / 3 antigenic peptides and MTA1-A2 antigenic peptides. The kit can efficiently activate prostatic cancer specific immunity response in an active inducing / passive inducing combined mode.

Description

technical field [0001] The invention relates to a kit for enhancing anticancer immunity, in particular to a kit for activating prostate cancer specific immune response. Background technique [0002] Prostate cancer refers to epithelial malignant tumors that occur in the prostate. According to the 2004 WHO "Pathology and Genetics of Tumors of the Urinary System and Male Reproductive Organs", the pathological types of prostate cancer include adenocarcinoma (acinar adenocarcinoma), ductal adenocarcinoma, urothelial carcinoma, squamous cell carcinoma, and adenosquamous carcinoma. . Among them, prostate adenocarcinoma accounts for more than 95%. Therefore, what we usually call prostate cancer refers to prostate adenocarcinoma. In 2012, the incidence rate of prostate cancer in my country's tumor registration areas was 9.92 / 100,000, ranking sixth in the incidence rate of male malignant tumors. The age of onset is at a low level before the age of 55, and gradually increases after...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/0784C12N5/0783A61K39/00A61P35/00
Inventor 李伟叶圣勤汪鑫瞿苏
Owner SHANGHAI LONGYAO BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com